LERU Briefing Paper: How to improve the development of Advanced Therapy Medicinal Products at universities

被引：0
|
作者：
Meij, P. [1 ]
Scott, M. [2 ,3 ]
Canals, J. M. [4 ,6 ,7 ,8 ]
Lowery, M. [5 ]
机构：
[1] Leiden Univ, Med Ctr, Dept Clin Pharm & Toxicol, Leiden, Netherlands
[2] Univ Cambridge, Sch Clin Med, Cambridge, England
[3] Advent Bioserv, Cambridge, England
[4] Univ Barcelona, Lab Stem Cells & Regenerat Med, Barcelona, Spain
[5] Univ Dublin, Trinity Coll Dublin, Dublin, Ireland
[6] Univ Barcelona, Creatio Prod & Validat Ctr Adv therapies, Barcelona, Spain
[7] August Pi i Sunyer Biomed Res Inst IDIBAPS, Barcelona, Spain
[8] Networked Biomed Res Ctr Neurodegenerat Disorders, Madrid, Spain
来源：
CYTOTHERAPY | 2020年 / 22卷 / 05期
关键词：
D O I：
暂无
中图分类号：
Q813 [细胞工程];
学科分类号：
摘要：
345
引用
收藏
页码：S165 / S166
页数：2
相关论文
共 50 条
  • [41] Human nasal olfactory stem cells, purified as advanced therapy medicinal products, improve neuronal differentiation
    Jaloux, Charlotte
    Bonnet, Maxime
    Vogtensperger, Marie
    Witters, Marie
    Veran, Julie
    Giraudo, Laurent
    Sabatier, Florence
    Michel, Justin
    Legre, Regis
    Guiraudie-Capraz, Gaelle
    Feron, Francois
    FRONTIERS IN NEUROSCIENCE, 2022, 16
  • [42] Advanced Therapy Medicinal Products for Rare Diseases: State of Play of Incentives Supporting Development in Europe
    Farkas, Andreas M.
    Mariz, Segundo
    Stoyanova-Beninska, Violeta
    Celis, Patrick
    Vamvakas, Spiros
    Larsson, Kristina
    Sepodes, Bruno
    FRONTIERS IN MEDICINE, 2017, 4
  • [43] Development of a UK national network of GMP facilities for the manufacture of advanced therapy medicinal products (ATMPs)
    Hollyman, D.
    Austin, E.
    Smith, K.
    Hadley, A.
    Bateman, I.
    Gillan, H.
    Lloyd-Evans, P.
    Watt, S. M.
    BONE MARROW TRANSPLANTATION, 2013, 48 : S511 - S511
  • [44] Challenges in development, market authorisation and commercialisation of advanced therapy medicinal products in Europe: A cohort study
    ten Ham, ten Renske M. T.
    Hoekman, Jarno
    Hovels, Anke M.
    Broekmans, Andre W.
    Leufkens, Hubert G. M.
    Klungel, Olaf H.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2018, 27 : 428 - 428
  • [45] Advanced Therapy Medicinal Products for Eye Diseases: Goals and Challenges
    Diebold, Yolanda
    Garcia-Posadas, Laura
    PHARMACEUTICS, 2021, 13 (11)
  • [46] THE REGULATION OF ADVANCED THERAPY MEDICINAL PRODUCTS IN EUROPE AND THE ROLE OF ACADEMIA
    Pearce, K. F.
    Hildebrandt, M. O.
    Scheding, S.
    Koehl, U.
    Mischak-Weissinger, E.
    Hauser, A.
    Edinger, M.
    Greinix, H.
    Worel, N.
    Apperley, J.
    Lowdell, M. W.
    Dickinson, A. M.
    CYTOTHERAPY, 2013, 15 (04) : S51 - S52
  • [47] The New Regulation of Advanced Therapy Medicinal Products in the European Union
    Ruiz, Sol
    MOLECULAR THERAPY, 2009, 17 : S395 - S395
  • [48] Payer and Implementation Challenges with Advanced Therapy Medicinal Products (ATMPs)
    John Spoors
    Alec Miners
    John Cairns
    Danny Palnoch
    Ash Summerfield
    Joanne McEntee
    Sheena Vithlani
    BioDrugs, 2021, 35 : 1 - 5
  • [49] Payer and Implementation Challenges with Advanced Therapy Medicinal Products (ATMPs)
    Spoors, John
    Miners, Alec
    Cairns, John
    Palnoch, Danny
    Summerfield, Ash
    McEntee, Joanne
    Vithlani, Sheena
    BIODRUGS, 2021, 35 (01) : 1 - 5
  • [50] Advanced Therapy Medicinal Products: Availability, Access and Expenditure in Italy
    Cervo, Pia Rivetti di Val
    Alessi, Eva
    Lastella, Marilena
    La Greca, Antonio
    Trotta, Francesco
    BIODRUGS, 2024, 38 (06) : 831 - 844
12345